Harvard Bioscience: A 73% Tape Rally That Finally Delivered a Growth Quarter

Q2 revenue up 11%, guidance raised, but margin mix and debt keep the turnaround thesis nuanced.

HBIO · Earnings Call · 2026-08-11

A Quarter That Breaks the Trend

Harvard Bioscience's second-quarter print was a shock to the tape. The stock has rallied 73% in the last 90 days even as the broader life-science tools complex wobbled. That move is a bet that the long, painful decline — total revenue still sits 30% below its 2019 peak — has finally bottomed. The quarter delivered what investors have been waiting for: 11% year-over-year growth to $22.7M, double-digit growth across both the CMT product lines and preclinical portfolios, and a raise to full-year revenue growth to 3–5%. As CEO John Duke put it, “double-digit revenue growth across our CMT and preclinical portfolios and solid operational execution that reinforced our confidence in raising our full-year revenue outlook” — John Duke, President and Chief Executive Officer · 2026-08-11. But the optics are mixed. The growth is real, but margin pressure is the trade-off. Adjusted gross margin came in at 57%, down from 56.4% last year, pressured by a mix shift toward lower-margin CMT and China sales. As CFO Mark Frost noted, “The decline was caused by a product and geographic mix shift with higher-than-expected CMT sales and strong demand in China, both of which carry relative lower gross margins” — Mark Frost, Chief Financial Officer · 2026-08-11. That's a deliberate choice, and one that pays off if it accelerates the installed base for the recurring revenue engine.

The Recurring Revenue Engine

The most important strategic pivot is the push to recurring revenue, now at 55% of total revenue, up 1 point in the half, with a target of 60%. That's anchored on BTX electroporation consumables, telemetry implants, and software licenses. The NPI platforms — SoHo telemetry, Mesh MEA organoid systems, and the AAA bioprocessing line — are growing double digits, and AAA bioprocessing was cited as a particular driver. Mark Frost noted that NPI revenue contributed 11% of revenue versus 3% a year ago. The mix shift to CMT and China may drag gross margin near-term, but if the recurring stream continues to build, it should more than compensate. China was a standout: APAC revenue up 24% yoy, with China itself up 29% to $3.1M, driven by CRO demand and the sales in China from the Made in China localization initiative. The company is actively shipping localized BTX units and expects further certifications in H2. That's a welcome reversal from the 2025 tariff shock that had China business nearly grind to a halt.

Researchers are adopting our products to generate more predictive, human-relevant data and address key preclinical translational challenges. We are increasingly seeing our execution across our strategic focus translate into tangible operational progress across our customer mix, product portfolio, and recurring revenue profile.
John Duke, President and Chief Executive Officer · 2026-08-11

Project Viking and the Balance Sheet

The other major leg of the story is cost discipline. Project Viking — the manufacturing footprint consolidation out of Holliston — is on track to deliver $3M in cost savings in 2027 and $4M annually thereafter. Management already transitioned two product lines in Q2 and will move two more in Q3. The company is also marketing the Holliston lease, though Mark Frost conceded a sub-tenant likely won't close until Q4 or Q1. The balance sheet remains a watch item. Net debt stood at $33.5M, up ~$5.6M yoy, with total debt of $36.7M. Cash used in operations was $0.3M in the first half versus $5.7M generated a year earlier — driven by inventory builds for Viking pre-build requirements and higher interest costs. Effective net cash swung from -$29M to -$33M in the quarter, but the December 2025 refinancing removed near-term amortization and provides some flexibility.

Market Context: Riding a Global Wave?

The broader tape has seen a rotation into life-science tools and the "high power laser" theme (up 411% over 360d), but HBIO's move is more idiosyncratic. Global keywords around IEEPA tariff refund and tariff normalization appear across many reporters — a tailwind that helped HBIO's China baseline reset. The academic market, which had been a drag, is “gradually improving” — John Duke, President and Chief Executive Officer · 2026-08-11 per John Duke, with NIH funds starting to flow — a theme from the prior call: “we are seeing what I would call an unthawing where basically funds, as you know, the reconciliation bill got approved February 3” — John Duke, President and Chief Executive Officer · 2026-05-12. That same thesis was echoed in Q4 2025: “we did see an improved benefit from all the NPIs we've launched” — Mark Frost, Interim Chief Financial Officer · 2025-11-07. The question is whether the market is pricing in a sustained re-rating. At $24M market cap and a Price-to-Revenue of 2.5x, the stock is still cheap versus its 2021 peak of 30x, but the recent 90-day rally has already moved it sharply. If the recurring revenue strategy holds and Viking cost savings land, the EBITDA growth guidance of 6–10% could prove conservative. But if the mix shift persists and gross margin stays below 60%, the path to profitability remains long. This is a small-cap turnaround story with real evidence of execution — and a tape that's already voting with conviction.